Close Menu

NEW YORK – Diagnostic firm Mologic said on Thursday it received the CE mark for its COVID-19 Rapid Antigen Test.

In preliminary findings in 28 symptomatic patients with PCR-confirmed COVID-19, the test diagnosed infection with a sensitivity of 92 percent and specificity of 100 percent.

The Bedfordshire, UK-based company is now planning additional UK studies at St. George’s University of London, Northumbria Healthcare NHS Foundation Trust, Imperial College London, Nottingham University Health Trust, and the Hull Royal Infirmary, and plans to report findings in January 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.